Azitra (AZTR) Times Interest Earned (2022 - 2026)
Azitra's (AZTR) quarterly Times Interest Earned came in at -$1056.4 in Q1 2026, down 56.09% YoY from -$2405.9 in Q1 2025, and down 74.72% on a QoQ basis from -$604.61 in Q4 2025.
Azitra (AZTR) Times Interest Earned (2022 - 2026) Analysis & Trends
Azitra (AZTR) has 5 years of Times Interest Earned data on file, last reported at -$1056.4 in Q1 2026.
- Quarterly Times Interest Earned fell 56.09% year-over-year to -$1056.4 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$670.24 (down 5.84% YoY) and the FY2025 annual result came in at -$0.55, up 16.81% from the prior year.
- Times Interest Earned declined to -$1056.4 in Q1 2026, from -$604.61 in the prior quarter.
- In the past five years, Times Interest Earned ranged from a high of -$4.89 in Q2 2025 to a low of -$1447.3 in Q4 2023.
- A 5-year average of -$469.67 and a median of -$519.17 in 2025 frame the typical range for Times Interest Earned.
- Annual changes were most pronounced in 2023 — Times Interest Earned tumbled 9829.34% — and 2025, when it soared 99.35%.
- Tracing AZTR's Times Interest Earned over 5 years: stood at -$14.58 in 2022, then plunged by 9829.34% to -$1447.3 in 2023, then surged by 70.03% to -$433.74 in 2024, then tumbled by 39.39% to -$604.61 in 2025, then plunged by 74.72% to -$1056.4 in 2026.
- The last three Times Interest Earned figures came in at -$1056.4 (Q1 2026), -$604.61 (Q4 2025), and -$103.95 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Times Interest Earned (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 117.59 |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 8.18 |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 2.82 |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 76.86 |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -0.08 |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 1.42 |
| 10 | Azitra | 2.53 Mn | 2.53 Mn | - | -2,504.88 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -8.14 |
| Mar 31, 2026 | -1,056.37 |
| Dec 31, 2025 | -604.61 |
| Sep 30, 2025 | -103.95 |
| Jun 30, 2025 | -4.89 |
| Mar 31, 2025 | -676.76 |
| Dec 31, 2024 | -433.74 |
| Sep 30, 2024 | -760.64 |
| Jun 30, 2024 | -755.33 |
| Mar 31, 2024 | -717.76 |
| Dec 31, 2023 | -1,447.26 |
| Sep 30, 2023 | -709.77 |
| Jun 30, 2023 | -18.74 |
| Mar 31, 2023 | -17.35 |
| Dec 31, 2022 | -14.58 |
| Sep 30, 2022 | -75.65 |
| Jun 30, 2022 | -117.25 |